Intuitive Doesn't Sell Robots. It Sells the Razor and Owns Every Blade.

A hospital signs a check for well over a million dollars, and a da Vinci surgical system arrives. That is the part everyone notices - the four-armed machine, the surgeon hunched over a console, the marketing brochure that says the future of surgery has been delivered. It is also the part Intuitive Surgical cares about least. The system is not the product. It is the cost of admission to a stream of payments the hospital will keep making, procedure after procedure, for the entire decade that machine sits in the operating room. In 2024, instruments and accessories alone brought Intuitive roughly $5.08 billion² - and recurring revenue, counting service, was 84% of the company's roughly $8.35 billion total.³ Sell the robot once. Get paid every time it cuts.

The official story is that this is a robotics company. It is really a consumables company that gives away a robot to sell the blades. Intuitive built the razor-and-handle business that razor blades were named for - except the handle costs seven figures, and once a hospital owns one, the cheapest thing it can possibly do is keep buying Intuitive's blades forever.

Why switching is irrational even when nobody forces you

The instinct is to assume lock-in is a clause - a contract that traps the hospital. The deeper truth is that Intuitive barely needs the clause, because the economics do the trapping on their own. Three sunk costs stack on top of each other. First, the capital: the machine is bought, depreciated, and budgeted for years, and a finance department does not write off a seven-figure asset to chase a rival. Second, the surgeon: a urologist or gynecologist trains for hundreds of cases on the da Vinci console, building muscle memory in one specific instrument set - and that training does not transfer to a competing platform any more than a pianist's hands transfer to a violin. Third, the consumable: every procedure consumes Intuitive's own EndoWrist instruments, which no one else may legally service, so the marginal cost of one more operation flows straight back to Intuitive. By the time a hospital might consider switching, it would be throwing away the machine, retraining every surgeon, and abandoning a procedure workflow that already runs. The math says stay. The geography of the operating room does the rest.

The use counter that turned a part into a subscription

Here is where the design got pointed. For years, core EndoWrist instruments carried a programmed usage limit - the famous cap of ten uses, after which the instrument stopped working and had to be replaced.⁸ An instrument that physically still functions but refuses to is not a worn-out tool; it is a meter. It converts a durable part into a metered subscription, billed to the hospital ten cases at a time. And when third parties offered to repair and reset those instruments more cheaply, Intuitive's stated position was that doing so 'constitute[s] remanufacturing under FDA regulations and require[s] 510(k) clearance from FDA'⁵ - a regulatory wall around the one part of the value chain a competitor could otherwise undercut. The handle was given away. The blade was locked.

But notice what Intuitive did next, because it is the most strategically interesting move in the whole story. In 2020 it launched an Extended Use Program and revalidated many core X and Xi instruments for 12 to 18 uses instead of 10 - cutting price per use by an average of 24%.⁴ By the company's own account, U.S. and European customers had cut over to the extended-use instruments by the end of 2021.⁸ On the surface, that looks like generosity. Read it as defense. The ten-use counter was the single most attackable feature of the model - the one a regulator or a jury could most easily call coercive - so Intuitive softened the most controversial lever before someone forced it to. You do not raise the cap on your own cash cow unless you can see the litigation coming.

Did the courts just bless all of this?

The honest objection is that maybe none of this is a problem at all - that a rival sued, lost, and the model stands vindicated. That reading is too tidy. It is true that in January 2025 Intuitive won the SIS trial: a repair company had argued it could service an EndoWrist at 55 to 70% of Intuitive's price and was being shut out, but the court ruled it failed to prove a cognizable 'aftermarket' under Ninth Circuit law, leaning on the reasoning in Epic Games v. Apple.⁶ That is a win on a narrow doctrine, not a clean bill of health for the lock-in itself. Because the bigger fight is still live: the consolidated hospital class action, In re Da Vinci Surgical Robot Antitrust Litigation, alleges Intuitive conditions buying or leasing the system on a sole-source service contract and ties EndoWrist replacements exclusively to itself - and on March 21, 2025, the court granted class certification covering a class of hospitals.⁷ The safety-only rationale for the use counter is contested, not settled; expert testimony in the SIS case challenged it directly, and the court declined to hand Intuitive that defense on summary judgment.⁶ So the position is strong and growing - the installed base reached 11,106 systems by the end of 2025¹ - but it is being tested by thousands of its own customers in open court.

Intuitive sells surgeons a console and sells hospitals a future, but it bills them on the only thing that truly compounds: the cut itself. The genius was never the robot - clever as it is. It was choosing to stand at the point every single procedure has to pass through, give the machine away as bait, and let two and a half million operations a year drag its consumables through the wound. The flywheel runs on the one thing a hospital can never take back: everything it already sank in. The open question, now sitting before a judge, is whether that flywheel was built on cost - or on a counter.